서울대학교 중앙도서관
S-Space 소개
My S-Space
로그인이 필요합니다.
Login

S-Space

Browse

Author

Jump to a point in the index
Or type in a year

  • Sort by
  • In order
  • Results/Page
  • Authors/record

Showing results 1 to 32 of 32

Issue DateTitle / Author(s) / CitationFileAltmetrics
2014-01
Adenoid Cystic Carcinoma of the Breast: A Case Series of Six Patients and Literature Review
DOI
2014-04
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors vs Conventional Chemotherapy in Non-Small Cell Lung Cancer Harboring Wild-Type Epidermal Growth Factor Receptor A Meta-analysis

Lee, June-Koo; Hahn, Seokyung; Kim, Dong-Wan; Suh, Koung Jin; Keam, Bhumsuk; Kim, Tae Min; Lee, Se-Hoon; Heo, Dae Seog

JAMA - Journal of the American Medical Association, Vol.311 No.14, pp.1430-1437

DOI
2014-12
HER2 Heterogeneity Affects Trastuzumab Responses and Survival in Patients With HER2-Positive Metastatic Breast Cancer
DOI
2015-07
Distinctive role of SIRT1 expression on tumor invasion and metastasis in breast cancer by molecular subtype
DOI
2016-07
Serum Neuron-Specific Enolase Levels Predict the Efficacy of First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations
DOI
2016-07
Prognostic impact of AJCC response criteria for neoadjuvant chemotherapy in stage II/III breast cancer patients: breast cancer subtype analyses
DOI
2016-07
Loss of ataxia-telangiectasia-mutated protein expression correlates with poor prognosis but benefits from anthracycline-containing adjuvant chemotherapy in breast cancer
DOI
2017-04
Efficacy of Letrozole as First-Line Treatment of Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer in Korea
DOI
2017-09
EGFR or HER2 inhibition modulates the tumor microenvironment by suppression of PD-L1 and cytokines release
DOI
2017-10
Bilateral Salpingo-oophorectomy Compared to Gonadotropin-Releasing Hormone Agonists in Premenopausal Hormone Receptor-Positive Metastatic Breast Cancer Patients Treated with Aromatase Inhibitors
DOI
2018-03
Post-treatment neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-PD-1 antibody
DOI
2018-03
Integrated 18F-FDG PET/MRI in breast cancer: Early prediction of response to neoadjuvant chemotherapy

Cho, Nariya; Im, Seock-Ah; Cheon, Gi Jeong; Park, In-Ae; Lee, Kyung-Hun; Kim, Tae-Yong; Kim, Young Seon; Kwon, Bo Ra; Lee, Jung Min; Suh, Hoon Young; Suh, Koung Jin

European Journal of Nuclear Medicine and Molecular Imaging, Vol.45 No.3, pp.328-339

DOI
2018-12
Androgen receptor inhibitor enhances the antitumor effect of PARP inhibitor in breast cancer cells by modulating DNA damage response
DOI
2019-04
Pan-PIM kinase inhibitor AZD1208 suppresses tumor growth and synergistically interacts with AKT inhibition in gastric cancer cells
DOI
2019-05
Prognostic effects of abnormal DNA damage response protein expression in breast cancer
DOI
2019-07
Immune recurrence score using 7 immunoregulatory protein expressions can predict recurrence in stage I–III breast cancer patients
DOI
2019-08
Enhanced antitumor effect of binimetinib in combination with capecitabine for biliary tract cancer patients with mutations in the RAS/RAF/MEK/ERK pathway: Phase Ib study
DOI
2020-04
Prognostic role of androgen receptor expression in surgically resected early breast cancer patients
DOI
2020-07
Homologous repair deficiency score for identifying breast cancers with defective DNA damage response
DOI
2020-07
Immunogenicity of influenza vaccination in patients with cancer receiving immune checkpoint inhibitors
DOI
2021-01
Clinical pattern of failure after a durable response to immune check inhibitors in non-small cell lung cancer patients
DOI
2021-02
Programmed death-ligand 1 expression level as a predictor of EGFR tyrosine kinase inhibitor efficacy in lung adenocarcinoma
DOI
2021-03
Tumor LAG-3 and NY-ESO-1 expression predict durable clinical benefits of immune checkpoint inhibitors in advanced non-small cell lung cancer
DOI
2021-12
R-MPV followed by high-dose chemotherapy with thiotepa-based and autologous stem cell transplantation for newly diagnosed primary central nervous system lymphoma: a single-center experience
DOI
2022-01
Clinical characteristics and disease course of splanchnic vein thrombosis in gastrointestinal cancers: A prospective cohort study
DOI
2022-04
Performance of clinician prediction of survival in oncology outpatients with advanced cancer
DOI
2022-04
A Real-World Efficacy of Nab-Paclitaxel Monotherapy in Metastatic Breast Cancer
DOI
2022-06
Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non-Small-Cell Lung Cancer
DOI
2022-07
The association between changes in symptoms or quality of life and overall survival in outpatients with advanced cancer
DOI
2022-09
Response Rate and Safety of a Neoadjuvant Pertuzumab, Atezolizumab, Docetaxel, and Trastuzumab Regimen for Patients With ERBB2-Positive Stage II/III Breast Cancer: The Neo-PATH Phase 2 Nonrandomized Clinical Trial
DOI
2022-11
Prognostic role of tumor subtype and germline BRCA mutation in advanced breast cancer patients treated with palbociclib plus endocrine therapy
DOI
2023-12
Clinical activity of nivolumab in combination with eribulin in HER2-negative metastatic breast cancer: A phase IB/II study (KCSG BR18-16)
DOI
1